FDA gives Dako nod on rapid cancer diagnostic test

02/18/2013 | GenomeWeb Daily News (free registration)

Dako has received approval from the FDA to market its HER2 IQFISH pharmDx test, which is used to cut the turnaround time for cancer diagnosis from the industry standard of two days to three and a half hours. The test, which identifies the HER2 gene in breast cancer diagnosis, is the first FDA-approved test that works with Dako's IQISH system, the company said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID